Qun Yin

USPTO Granted Patents = 30 (Patent Applications = 14)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 3.6

ph-index = 7

Forward Citations = 350(Granted Patents)

Location History:

Sunnyvale, CA (US) (1999 - 2003)
Palo Alto, CA (US) (2006 - 2024)

Company Filing History:

Kai Pharmaceuticals, Inc.

Sutro Biopharma, Inc.

Years Active: 1999-2024

Loading Chart...

30 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11959486 - Stable liquid formulation of AMG 416 (etelcalcetide) (2024-04-16),

2. 11866515 - Hemiasterlin derivatives for conjugation and therapy (2024-01-09),

3. 11162500 - Stable liquid formulation of AMG 416 (etelcalcetide) (2021-11-02),

4. 10844090 - Hemiasterlin derivatives for conjugation and therapy (2020-11-24),

5. 10442789 - Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use (2019-10-15),

6. 10344765 - Stable liquid formulation of AMG 416 (etelcalcetide) (2019-07-09),

7. 10280198 - Therapeutic agents for reducing parathyroid hormone levels (2019-05-07),

8. 9840493 - Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use (2017-12-12),

9. 9820938 - Stable liquid formulation of AMG 416 (etelcalcetide) (2017-11-21),

10. 9701712 - Therapeutic agents for reducing parathyroid hormone levels (2017-07-11),

11. 9567370 - Therapeutic agents for reducing parathyroid hormone levels (2017-02-14),

12. 9278995 - Therapeutic agents for reducing parathyroid hormone levels (2016-03-08),

13. 8999932 - Therapeutic agents for reducing parathyroid hormone levels (2015-04-07),

14. 8729030 - Peptides that bind to the erythropoietin receptor (2014-05-20),

15. 8592365 - Spacer moiety for poly(ethylene glycol) modified peptide based compounds (2013-11-26),

Title: Qun Yin: Innovator in Pharmaceutical Development

Introduction: Qun Yin, located in Palo Alto, California, is a prolific inventor with a noteworthy portfolio of 30 patents. His contributions to the field of pharmaceutical formulations and therapies demonstrate his innovative approach to addressing complex medical challenges. Qun's work has significant implications for the treatment of various health conditions, particularly in cancer therapy and calcium metabolism disorders.

Latest Patents: Among Qun Yin's latest inventions is a patent for a stable liquid formulation of AMG 416 (etelcalcetide). This formulation comprises a peptide agonist of the calcium-sensing receptor, alongside methods for its preparation and usage. Another recent patent focuses on hemiasterlin derivatives for conjugation and therapy. These derivatives, conjugates, and compositions play a crucial role in the treatment and prevention of cell proliferation and cancer. Moreover, they facilitate methods for detection and diagnosis of these conditions, showcasing Qun’s commitment to advancing medical science.

Career Highlights: Qun Yin's career is marked by significant roles in leading biotechnology companies, including Affymax, Inc. and Kai Pharmaceuticals, Inc. His research and development efforts in these organizations have contributed to groundbreaking innovations in drug formulations and therapeutic applications.

Collaborations: Throughout his career, Qun has collaborated with notable professionals such as Derek Maclean and Peter J. Schatz. These partnerships have enriched his work, fostering an environment of innovation and leading to the enhancement of pharmaceutical therapies.

Conclusion: Qun Yin stands out as a distinguished inventor in the realm of pharmaceuticals. His extensive patent portfolio and collaborative achievements underscore his commitment to advancing healthcare solutions. As he continues to innovate, the impact of his work will likely resonate within the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.